ATE283289T1 - Monoklonale antikörper, antigene sowie diagnose und therapie von bösartigen krankheiten - Google Patents
Monoklonale antikörper, antigene sowie diagnose und therapie von bösartigen krankheitenInfo
- Publication number
- ATE283289T1 ATE283289T1 AT99973801T AT99973801T ATE283289T1 AT E283289 T1 ATE283289 T1 AT E283289T1 AT 99973801 T AT99973801 T AT 99973801T AT 99973801 T AT99973801 T AT 99973801T AT E283289 T1 ATE283289 T1 AT E283289T1
- Authority
- AT
- Austria
- Prior art keywords
- peptides
- mabs
- malignant diseases
- monoclonal antibodies
- antigens
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56966—Animal cells
- G01N33/56972—White blood cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57415—Specifically defined cancers of breast
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57419—Specifically defined cancers of colon
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57434—Specifically defined cancers of prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IL12929999A IL129299A0 (en) | 1999-03-31 | 1999-03-31 | Monoclonal antibodies antigens and diagnosis of malignant diseases |
PCT/IL1999/000518 WO2000058363A1 (en) | 1999-03-31 | 1999-09-30 | Monoclonal antibodies, antigens and diagnosis and therapy of malignant diseases |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE283289T1 true ATE283289T1 (de) | 2004-12-15 |
Family
ID=11072675
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT99973801T ATE283289T1 (de) | 1999-03-31 | 1999-09-30 | Monoklonale antikörper, antigene sowie diagnose und therapie von bösartigen krankheiten |
Country Status (16)
Country | Link |
---|---|
US (2) | US20030026800A1 (de) |
EP (1) | EP1165616B1 (de) |
JP (1) | JP2003500015A (de) |
KR (1) | KR20020008140A (de) |
CN (1) | CN1267452C (de) |
AT (1) | ATE283289T1 (de) |
AU (1) | AU776464C (de) |
BR (1) | BR9917218A (de) |
CA (1) | CA2367901C (de) |
DE (1) | DE69922261T2 (de) |
HU (1) | HUP0200537A2 (de) |
IL (3) | IL129299A0 (de) |
NZ (1) | NZ513498A (de) |
RU (1) | RU2235131C2 (de) |
WO (1) | WO2000058363A1 (de) |
ZA (1) | ZA200106809B (de) |
Families Citing this family (69)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1225233A3 (de) * | 2001-01-23 | 2003-01-08 | Amsterdam Support Diagnostics B.V. | Mittel und Methoden für die Abschätzung einer Behandlung |
IL145926A0 (en) * | 2001-10-15 | 2002-07-25 | Mor Research Applic Ltd | Peptide epitopes of mimotopes useful in immunomodulation |
IL149820A0 (en) | 2002-05-23 | 2002-11-10 | Curetech Ltd | Humanized immunomodulatory monoclonal antibodies for the treatment of neoplastic disease or immunodeficiency |
WO2006021955A2 (en) * | 2004-08-23 | 2006-03-02 | Mor Research Applications Ltd. | Use of bat monoclonal antibody for immunotherapy |
SG172684A1 (en) * | 2006-06-07 | 2011-07-28 | Bioalliance Cv | Antibodies recognizing a carbohydrate containing epitope on cd-43 and cea expressed on cancer cells and methods using same |
CA2855098C (en) | 2007-06-18 | 2018-02-27 | Merck Sharp & Dohme B.V. | Antibodies to human programmed death receptor pd-1 |
RU2531758C2 (ru) * | 2008-02-11 | 2014-10-27 | Куретек Лтд. | Моноклональные антитела для лечения опухолей |
US9416132B2 (en) | 2011-07-21 | 2016-08-16 | Tolero Pharmaceuticals, Inc. | Substituted imidazo[1,2-b]pyridazines as protein kinase inhibitors |
BR112013032552A2 (pt) | 2011-07-24 | 2017-12-12 | Curetech Ltd | variantes de anticorpos monoclonais humanizados imunomoduladores |
AR089028A1 (es) * | 2011-11-29 | 2014-07-23 | Genentech Inc | Composiciones y metodos para el analisis de cancer de prostata |
EP3757130A1 (de) | 2013-09-26 | 2020-12-30 | Costim Pharmaceuticals Inc. | Verfahren zur behandlung von blutkrebs |
US9580504B1 (en) | 2013-11-07 | 2017-02-28 | Curetech Ltd. | Pidilizumab monoclonal antibody therapy following stem cell transplantation |
JOP20200094A1 (ar) | 2014-01-24 | 2017-06-16 | Dana Farber Cancer Inst Inc | جزيئات جسم مضاد لـ pd-1 واستخداماتها |
JOP20200096A1 (ar) | 2014-01-31 | 2017-06-16 | Children’S Medical Center Corp | جزيئات جسم مضاد لـ tim-3 واستخداماتها |
EP3659621A1 (de) | 2014-09-13 | 2020-06-03 | Novartis AG | Kombinationstherapien gegen krebs |
PE20181322A1 (es) | 2015-09-01 | 2018-08-14 | Agenus Inc | Anticuerpo anti-pd1 y sus metodos de uso |
MA44236A (fr) | 2016-02-17 | 2018-12-26 | Novartis Ag | Anticorps anti-tgfbêta 2 |
WO2017218533A1 (en) | 2016-06-13 | 2017-12-21 | Torque Therapeutics, Inc. | Methods and compositions for promoting immune cell function |
US11279694B2 (en) | 2016-11-18 | 2022-03-22 | Sumitomo Dainippon Pharma Oncology, Inc. | Alvocidib prodrugs and their use as protein kinase inhibitors |
EP3570870A1 (de) | 2017-01-20 | 2019-11-27 | Novartis AG | Kombinationstherapie zur behandlung von krebs |
AU2018217963B2 (en) | 2017-02-10 | 2020-11-19 | Novartis Ag | 1-(4-amino-5-bromo-6-(1 H-pyrazol-1-yl)pyrimidin-2-yl)-1 H-pyrazol-4-ol and use thereof in the treatment of cancer |
AR111760A1 (es) | 2017-05-19 | 2019-08-14 | Novartis Ag | Compuestos y composiciones para el tratamiento de tumores sólidos mediante administración intratumoral |
JOP20190279A1 (ar) | 2017-05-31 | 2019-11-28 | Novartis Ag | الصور البلورية من 5-برومو -2، 6-داي (1h-بيرازول -1-يل) بيريميدين -4- أمين وأملاح جديدة |
WO2018229715A1 (en) | 2017-06-16 | 2018-12-20 | Novartis Ag | Compositions comprising anti-cd32b antibodies and methods of use thereof |
WO2018237173A1 (en) | 2017-06-22 | 2018-12-27 | Novartis Ag | ANTIBODY MOLECULES DIRECTED AGAINST CD73 AND CORRESPONDING USES |
EP3641812A1 (de) | 2017-06-22 | 2020-04-29 | Novartis AG | Antikörpermoleküle gegen cd73 und verwendungen davon |
CN111050791A (zh) | 2017-06-27 | 2020-04-21 | 诺华股份有限公司 | 用于抗tim-3抗体的给药方案及其用途 |
CA3070095A1 (en) | 2017-07-20 | 2019-01-24 | Novartis Ag | Dosage regimens of anti-lag-3 antibodies and uses thereof |
WO2019055579A1 (en) | 2017-09-12 | 2019-03-21 | Tolero Pharmaceuticals, Inc. | TREATMENT REGIME FOR CANCERS THAT ARE INSENSITIVE TO BCL-2 INHIBITORS USING THE MCL-1 ALVOCIDIB INHIBITOR |
US20210040205A1 (en) | 2017-10-25 | 2021-02-11 | Novartis Ag | Antibodies targeting cd32b and methods of use thereof |
CN111655288A (zh) | 2017-11-16 | 2020-09-11 | 诺华股份有限公司 | 组合疗法 |
CA3083949A1 (en) | 2017-11-30 | 2020-06-06 | Novartis Ag | Bcma-targeting chimeric antigen receptor, and uses thereof |
CN112218651A (zh) | 2018-01-08 | 2021-01-12 | 诺华公司 | 用于与嵌合抗原受体疗法组合的免疫增强rna |
WO2019152660A1 (en) | 2018-01-31 | 2019-08-08 | Novartis Ag | Combination therapy using a chimeric antigen receptor |
US20200399383A1 (en) | 2018-02-13 | 2020-12-24 | Novartis Ag | Chimeric antigen receptor therapy in combination with il-15r and il15 |
US20210147547A1 (en) | 2018-04-13 | 2021-05-20 | Novartis Ag | Dosage Regimens For Anti-Pd-L1 Antibodies And Uses Thereof |
TW202015726A (zh) | 2018-05-30 | 2020-05-01 | 瑞士商諾華公司 | Entpd2抗體、組合療法、及使用該等抗體和組合療法之方法 |
WO2019232244A2 (en) | 2018-05-31 | 2019-12-05 | Novartis Ag | Antibody molecules to cd73 and uses thereof |
EP3802611A2 (de) | 2018-06-01 | 2021-04-14 | Novartis AG | Bindungsmoleküle gegen bcma und deren verwendungen |
WO2020021465A1 (en) | 2018-07-25 | 2020-01-30 | Advanced Accelerator Applications (Italy) S.R.L. | Method of treatment of neuroendocrine tumors |
WO2020044252A1 (en) | 2018-08-31 | 2020-03-05 | Novartis Ag | Dosage regimes for anti-m-csf antibodies and uses thereof |
WO2020049534A1 (en) | 2018-09-07 | 2020-03-12 | Novartis Ag | Sting agonist and combination therapy thereof for the treatment of cancer |
JP2022504905A (ja) | 2018-10-16 | 2022-01-13 | ノバルティス アーゲー | 標的化療法に対する応答を予測するためのバイオマーカーとしての単独の又は免疫マーカーと組み合わせた腫瘍突然変異負荷 |
US11034710B2 (en) | 2018-12-04 | 2021-06-15 | Sumitomo Dainippon Pharma Oncology, Inc. | CDK9 inhibitors and polymorphs thereof for use as agents for treatment of cancer |
CA3127502A1 (en) | 2019-02-12 | 2020-08-20 | Sumitomo Dainippon Pharma Oncology, Inc. | Formulations comprising heterocyclic protein kinase inhibitors |
CA3129031A1 (en) | 2019-02-12 | 2020-08-20 | Novartis Ag | Pharmaceutical combination comprising tno155 and a pd-1 inhibitor |
JP2022525149A (ja) | 2019-03-20 | 2022-05-11 | スミトモ ダイニッポン ファーマ オンコロジー, インコーポレイテッド | ベネトクラクスが失敗した急性骨髄性白血病(aml)の処置 |
US11712433B2 (en) | 2019-03-22 | 2023-08-01 | Sumitomo Pharma Oncology, Inc. | Compositions comprising PKM2 modulators and methods of treatment using the same |
US11529350B2 (en) | 2019-07-03 | 2022-12-20 | Sumitomo Pharma Oncology, Inc. | Tyrosine kinase non-receptor 1 (TNK1) inhibitors and uses thereof |
TW202124446A (zh) | 2019-09-18 | 2021-07-01 | 瑞士商諾華公司 | 與entpd2抗體之組合療法 |
US20220348651A1 (en) | 2019-09-18 | 2022-11-03 | Novartis Ag | Entpd2 antibodies, combination therapies, and methods of using the antibodies and combination therapies |
EP4048281A1 (de) | 2019-10-21 | 2022-08-31 | Novartis AG | Kombinationstherapien mit venetoclax und tim-3-inhibitoren |
JP2022553306A (ja) | 2019-10-21 | 2022-12-22 | ノバルティス アーゲー | Tim-3阻害剤およびその使用 |
US20230000864A1 (en) | 2019-11-22 | 2023-01-05 | Sumitomo Pharma Oncology, Inc. | Solid dose pharmaceutical composition |
AU2020406350A1 (en) | 2019-12-20 | 2022-08-11 | Novartis Ag | Uses of anti-TGF-beta antibodies and checkpoint inhibitors for the treatment of proliferative diseases |
US20230058489A1 (en) | 2020-01-17 | 2023-02-23 | Novartis Ag | Combination comprising a tim-3 inhibitor and a hypomethylating agent for use in treating myelodysplastic syndrome or chronic myelomonocytic leukemia |
JP2023516155A (ja) | 2020-02-28 | 2023-04-18 | ノバルティス アーゲー | ダブラフェニブ、erk阻害剤及びraf阻害剤又はpd-1阻害剤を含む三重の医薬品の組合せ |
BR112022021105A2 (pt) | 2020-04-21 | 2022-11-29 | Novartis Ag | Regime de dosagem para tratar uma doença modulada por csf-1r |
WO2022009157A1 (en) | 2020-07-10 | 2022-01-13 | Novartis Ag | Lhc165 and spartalizumab combinations for treating solid tumors |
EP4204021A1 (de) | 2020-08-31 | 2023-07-05 | Advanced Accelerator Applications International S.A. | Verfahren zur behandlung von psma-exprimierenden krebsarten |
WO2022043558A1 (en) | 2020-08-31 | 2022-03-03 | Advanced Accelerator Applications International Sa | Method of treating psma-expressing cancers |
WO2022097060A1 (en) | 2020-11-06 | 2022-05-12 | Novartis Ag | Cd19 binding molecules and uses thereof |
TW202237119A (zh) | 2020-12-10 | 2022-10-01 | 美商住友製藥腫瘤公司 | Alk﹘5抑制劑和彼之用途 |
TW202241935A (zh) | 2020-12-18 | 2022-11-01 | 美商世紀治療股份有限公司 | 具有可調適受體專一性之嵌合抗原受體系統 |
WO2022162569A1 (en) | 2021-01-29 | 2022-08-04 | Novartis Ag | Dosage regimes for anti-cd73 and anti-entpd2 antibodies and uses thereof |
EP4284919A1 (de) | 2021-01-29 | 2023-12-06 | Iovance Biotherapeutics, Inc. | Verfahren zur herstellung von modifizierten tumorinfiltrierenden lymphozyten und deren verwendung in der adoptiven zelltherapie |
TW202304979A (zh) | 2021-04-07 | 2023-02-01 | 瑞士商諾華公司 | 抗TGFβ抗體及其他治療劑用於治療增殖性疾病之用途 |
JP2024516371A (ja) | 2021-04-13 | 2024-04-15 | ヌバレント, インク. | Egfr変異を有するがんを処置するためのアミノ置換ヘテロ環類 |
WO2023147488A1 (en) | 2022-01-28 | 2023-08-03 | Iovance Biotherapeutics, Inc. | Cytokine associated tumor infiltrating lymphocytes compositions and methods |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5001225A (en) * | 1986-12-08 | 1991-03-19 | Georgetown University | Monoclonal antibodies to a pan-malarial antigen |
US5576184A (en) * | 1988-09-06 | 1996-11-19 | Xoma Corporation | Production of chimeric mouse-human antibodies with specificity to human tumor antigens |
US5571894A (en) * | 1991-02-05 | 1996-11-05 | Ciba-Geigy Corporation | Recombinant antibodies specific for a growth factor receptor |
IL108501A (en) | 1994-01-31 | 1998-10-30 | Mor Research Applic Ltd | Antibodies and pharmaceutical compositions containing them |
US5897882A (en) * | 1996-04-12 | 1999-04-27 | Gonzalez; Juan | Glass repair system |
TW517067B (en) * | 1996-05-31 | 2003-01-11 | Hoffmann La Roche | Interferon conjugates |
JP3886238B2 (ja) * | 1997-02-12 | 2007-02-28 | 中外製薬株式会社 | リンパ球系腫瘍の治療剤 |
JPH1142087A (ja) * | 1997-07-29 | 1999-02-16 | Sumitomo Electric Ind Ltd | 抗ヒトプレb細胞レセプター抗体およびその活性フラグメントならびにヒトプロb細胞の検出方法 |
US7442776B2 (en) * | 1999-10-08 | 2008-10-28 | Young David S F | Cancerous disease modifying antibodies |
IL149820A0 (en) | 2002-05-23 | 2002-11-10 | Curetech Ltd | Humanized immunomodulatory monoclonal antibodies for the treatment of neoplastic disease or immunodeficiency |
US7393531B2 (en) * | 2003-01-21 | 2008-07-01 | Arius Research Inc. | Cytotoxicity mediation of cells evidencing surface expression of MCSP |
-
1999
- 1999-03-31 IL IL12929999A patent/IL129299A0/xx unknown
- 1999-09-30 CN CNB998165425A patent/CN1267452C/zh not_active Expired - Fee Related
- 1999-09-30 NZ NZ513498A patent/NZ513498A/xx not_active IP Right Cessation
- 1999-09-30 EP EP99973801A patent/EP1165616B1/de not_active Expired - Lifetime
- 1999-09-30 WO PCT/IL1999/000518 patent/WO2000058363A1/en active IP Right Grant
- 1999-09-30 KR KR1020017012384A patent/KR20020008140A/ko not_active Application Discontinuation
- 1999-09-30 AU AU59965/99A patent/AU776464C/en not_active Ceased
- 1999-09-30 CA CA2367901A patent/CA2367901C/en not_active Expired - Fee Related
- 1999-09-30 DE DE69922261T patent/DE69922261T2/de not_active Expired - Lifetime
- 1999-09-30 AT AT99973801T patent/ATE283289T1/de not_active IP Right Cessation
- 1999-09-30 RU RU2001126052/13A patent/RU2235131C2/ru not_active IP Right Cessation
- 1999-09-30 HU HU0200537A patent/HUP0200537A2/hu unknown
- 1999-09-30 IL IL14553599A patent/IL145535A0/xx active IP Right Grant
- 1999-09-30 JP JP2000608655A patent/JP2003500015A/ja active Pending
- 1999-09-30 BR BR9917218-6A patent/BR9917218A/pt not_active IP Right Cessation
-
2001
- 2001-08-17 ZA ZA200106809A patent/ZA200106809B/en unknown
- 2001-09-21 IL IL145535A patent/IL145535A/en not_active IP Right Cessation
- 2001-09-28 US US09/967,719 patent/US20030026800A1/en not_active Abandoned
-
2005
- 2005-12-23 US US11/315,067 patent/US7695715B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
DE69922261T2 (de) | 2005-12-01 |
BR9917218A (pt) | 2001-12-26 |
RU2235131C2 (ru) | 2004-08-27 |
ZA200106809B (en) | 2002-08-19 |
CN1267452C (zh) | 2006-08-02 |
CA2367901A1 (en) | 2000-10-05 |
US20030026800A1 (en) | 2003-02-06 |
HUP0200537A2 (en) | 2002-06-29 |
AU5996599A (en) | 2000-10-16 |
US7695715B2 (en) | 2010-04-13 |
EP1165616A1 (de) | 2002-01-02 |
US20060099209A1 (en) | 2006-05-11 |
DE69922261D1 (de) | 2004-12-30 |
IL145535A (en) | 2008-06-05 |
EP1165616B1 (de) | 2004-11-24 |
JP2003500015A (ja) | 2003-01-07 |
CN1346371A (zh) | 2002-04-24 |
AU776464B2 (en) | 2004-09-09 |
IL145535A0 (en) | 2002-06-30 |
IL129299A0 (en) | 2000-02-17 |
WO2000058363A1 (en) | 2000-10-05 |
KR20020008140A (ko) | 2002-01-29 |
CA2367901C (en) | 2013-03-19 |
AU776464C (en) | 2005-05-12 |
NZ513498A (en) | 2004-01-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE283289T1 (de) | Monoklonale antikörper, antigene sowie diagnose und therapie von bösartigen krankheiten | |
MA30962B1 (fr) | Anticorps antifacteurs d'humanisés et leurs utilisations. | |
DE502005009602D1 (de) | Identifizierung von oberflächen-assoziierten antigenen für die tumordiagnose und -therapie | |
UA90082C2 (ru) | Выделенное моноклональное антитело человека, которое специфически связывается с cd25 человека и ингибирует связывание il-2 с cd25 | |
RU2001126052A (ru) | Моноклональные антитела, антигены и их применение для диагностики и терапии злокачественных заболеваний | |
ATE376559T1 (de) | Methoden der verhinderung und behandlung der alzheimer'schen krankheit | |
EA200700083A1 (ru) | Антитела, направленные против бета-амилоидного пептида, и способы их применения | |
AT500379B8 (de) | Tau-proteine | |
WO2004003155A3 (en) | Humanized anti-tag-72 cc49 for diagnosis and therapy of human tumors | |
EP2192407A3 (de) | Verfahren zum Nachweis von Zellimmunität und ihre Anwendung auf Arzneimittel | |
ES2284624T3 (es) | Metodo para diagnosticar la eficacia del tratamiento con anticuerpos xenotipicos. | |
ATE334145T1 (de) | Neues menschliches ulip/crmp protein und seine verwendung zur diagnose zur behandlung von krebs und von neurologischen paraneoplastischen syndromen | |
CN113667011B (zh) | 制备抗原结合单元的方法 | |
AU2001270518A1 (en) | Hypha-specific factors from candida albicans |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |